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INVITED REVIEW
CHAGAS DISEASE CARDIOMYOPATHY: CURRENT CONCEPTS OF AN OLD DISEASE
Angelina M.B.BILATE(1,4) & Edecio CUNHA-NETO(2,3,4)
SUMMARY
Chagas disease continues to be a significant public health problem, as ca. 10 million people are still infected with T. cruzi in
Latin America. Decades after primary infection, 30% of individuals can develop a form of chronic inflammatory cardiomyopathy
known as Chagas disease cardiomyopathy (CCC). Data from both murine models and human studies support the view that an
autoimmune response as well as a parasite-driven immune response involving inflammatory cytokines and chemokines may both
play a role in generating the heart lesions leading to CCC. This review aims to summarize recent advances in the understanding of
the immunopathogenesis of Chagas disease cardiomyopathy.
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CHAGAS DISEASE: AN OVERVIEW
In 1909, Brazilian physician Carlos Chagas took a significant step
in the advancement of Medicine by discovering Chagas disease and its
etiological agent, the protozoan parasite Trypanosoma cruzi. However,
despite efficient vector control programs to restrict the spread of Chagas
disease over the century since its discovery, the World Health
Organization estimates that ca. 10 million people are still infected by
T. cruzi in Latin America (SCHOFIELD et al., 2006), which makes
Chagas disease an important public health problem. Unfortunately,
Chagas disease remains a neglected disease, with no vaccines available
so far, and only very few anti-parasitic drugs proven efficient for treating
the acute phase of the disease. Moreover, the millions of people that
were infected decades ago are still in need of appropriate treatment,
and require the attention of the scientific community.
The general consequences of acute infection can range from flu-
like symptoms and asymptomatic myocarditis, which affects the
majority of infected individuals, to intense myocarditis accompanied
by high blood and tissue parasitism in about 10% of those infected
(CHAGAS, 1909; DIAS et al., 1956). This subset of individuals may
develop fulminant myocarditis, which is often fatal (PARADA et al.,
1997; ANDRADE, 1999). On the other hand, the majority of infected
individuals remain free of any clinical symptoms (the so-called
indeterminate patients, IND), but decades later may develop a form of
inflammatory cardiomyopathy known as chronic Chagas disease
cardiomyopathy (CCC). CCC affects 30% of infected patients and, in
some endemic areas, nearly 10% of all adult deaths are due to CCC.
Clinical progression and survival are significantly worse in CCC
patients as compared with patients with dilated cardiomyopathy (DCM)
of other etiologies (FREITAS et al., 2005) due to the lack of effective
therapies. The mechanisms that govern the pathogenesis of CCC remain
poorly understood. There are at least six proposed mechanisms for
CCC pathogenesis, including: (i) microvascular spasm, (ii) ischemia,
(iii) chronic eosinophilia or neutrophilia, (iv) parasite-mediated toxicity,
(v) anti-T. cruzi immune responses to parasites or parasite antigen that
persist in the heart, and (vi) T. cruzi-induced autoimmunity
(TANOWITZ et al., 1992; KIERSZENBAUM, 1996; KALIL &
CUNHA-NETO, 1996; KIERSZENBAUM, 1999; ENGMAN & LEON,
2002; LEON & ENGMAN, 2003; CUNHA-NETO et al., 2004). This
review aims to summarize recent advances in the understanding of the
immunopathogenesis of Chagas disease cardiomyopathy.
IMMUNOPATHOGENESIS OF CHAGAS DISEASE
CARDIOMYOPATHY
Autoimmunity X parasite persistence: CCC lesions are consistent
with a process of inflammation and myocardial remodeling, which
includes T cell/macrophage-rich myocarditis, hypertrophy, and fibrosis
with heart fiber damage (reviewed in HIGUCHI et al., 2003). Since
inflammation is one of the hallmarks of CCC lesions, one might
speculate as to its role in disease outcome. HIGUCHI and co-workers
showed that the frequency of myocarditis was higher among patients
with severe CCC than in patients with less severe forms of the disease
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(HIGUCHI et al., 1987). Accordingly, our group showed a significant
correlation between myocarditis and fibrosis and ventricular dilation
in the Syrian hamster model of CCC (BILATE et al., 2003). However,
in spite of the substantial evidence supporting a role for immune
responses in myocardial damage, the nature of the antigen eliciting
the destructive immune response remains elusive. The near absence of
parasites from severely inflamed heart tissue initially suggested that
lesions may be autoimmune in origin (the “autoimmune hypothesis,”
reviewed in CUNHA-NETO et al., 2006). The later discovery of
substantial autoimmune responses in both humans and experimental
animal models of disease reinforced this idea (reviewed in CUNHA-
NETO et al., 2006). On the other hand, the presence of parasite antigen
and DNA in host tissues during the chronic phase of Chagas disease
(reviewed in HIGUCHI et al., 2003), although very scarce, may be
relevant for maintaining T. cruzi-specific immune responses.
Furthermore, T. cruzi-specific CD8+ T cells have been isolated from
endomyocardial biopsies of a CCC patient (FONSECA et al., 2005),
providing evidence for the recruitment and expansion of T. cruzi-specific
T cells in the myocardium, possibly related to the presence of the
parasite antigen. In experimental T. cruzi infection, a higher inoculum
(BILATE et al., 2003) or higher parasite load in the acute phase
(MARINHO et al., 1999) are associated with more aggressive heart
disease, suggesting a relationship between parasite burden and severity
of disease in animal models. However, T. cruzi DNA - but not intact T.
cruzi - was detected in the hearts of both IND and CCC patients
(reviewed in CUNHA-NETO et al., 2006), which does not support an
association between parasite presence and CCC in humans. Other
factors must therefore be operating along with parasite persistence to
lead a subgroup of T. cruzi-infected individuals towards heart damage.
This led to the hypothesis that the breakdown of immunological
tolerance with heart tissue damage could be secondary to an originally
protective response directed to a given T. cruzi antigen bearing structural
similarities to a tissue-specific heart component. Several mechanisms
have been suggested to play a role in triggering autoimmunity after T.
cruzi infection (reviewed in CUNHA-NETO et al., 2006), including
(i) antigen exposure secondary to tissue damage, followed by
sensitization in an appropriate inflammatory environment (i.e.,
bystander activation); (ii) molecular mimicry, where T and B cells
recognize parasite antigens that share structurally similar epitopes in
host antigens, generating crossreactive autoimmune responses (Table
2); and (iii) polyclonal activation leading to autoantibody production.
In the following paragraphs, we discuss a number of significant findings
supporting some of these mechanisms.
T. cruzi-infected mice display autoantibodies specific for various
autoantigens contained in cardiac, nervous, and other tissues. These
include antibodies to structural proteins (e.g. desmin, myosin and actin)
and proteins with functional activities, such as β1-adrenergic and M2-
muscarinic cholinergic receptors (Table 1) (reviewed in CUNHA-NETO
et al., 2004). Immunization of mice with the T. cruzi protein cruzipain
induced autoantibodies to skeletal and cardiac myosin and to the cardiac
muscarinic cholinergic receptor, leading to muscle damage and heart
conduction abnormalities (GIORDANENGO et al., 2000). Another
notable finding was the development of autoreactive anti-heart
antibodies and heart functional alterations following the immunization
of BALB/c mice with T. cruzi ribosomal P1 and P2 protein synthetic
peptide (MOTRAN et al., 2000). See Table 2 for a complete list of all
T. cruzi cross-reactive antigens described so far.
Cellular autoimmunity directed at heart autoantigens has also been
observed in experimental Chagas disease. CD4+ T cells from T. cruzi-
infected mice recognize cardiac myosin but not actin (RIZZO et al.,
1989; LEON et al., 2001). Passive transfer of CD4+ T cells or T cell
lines from chronically T. cruzi-infected mice to noninfected syngeneic
mice cause myocardial tissue inflammation (RIBEIRO-DOS SANTOS
et al., 2001). Tolerance induction with a myosin-enriched cardiac
homogenate ameliorated chronic myocarditis and fibrosis in a mouse
model of T. cruzi infection (PONTES DE CARVALHO et al., 2002).
In humans, sera from Chagas disease patients but not from healthy
individuals was shown to contain autoantibodies specific for various
autoantigens expressed in cardiac, nervous, and other tissues (Table
1). One study reported finding anti-neuron antibodies in serum of over
80% of patients, accompanied by net loss of neurons from the
autonomic system. Functional antibodies against adrenergic and
muscarinic (M2) cholinergic receptors were found in serum from
arrhythmic CCC patients. These antibodies were capable of inducing
arrhythmia in explanted rabbit hearts (DE OLIVEIRA et al. 1997;
Tables 1 and 2). The presence of functionally active anti-receptor
antibodies may also correlate with dysfunction of the autonomic
nervous system, rather than with heart symptomatology (GOIN et al.,
1997).
Sera from chronic Chagas disease patients also contain antibodies
crossreactive with human and T. cruzi proteins, many of which are
evolutionarily conserved (Table 2). In particular, antibodies
crossreactive with cardiac myosin heavy chain and the T. cruzi protein
B13 are more frequent in sera from CCC than in indeterminate Chagas
disease patients (CUNHA-NETO et al., 1995). CD4+ T cell clones
derived from an endomyocardial biopsy sample taken from a CCC
patient crossreactively recognized T. cruzi protein B13 and cardiac
myosin, but not actin (CUNHA-NETO et al., 1996). In vitro
sensitization of human peripheral lymphocytes with B13 protein
Table 1
Autoreactivity after T. cruzi infection
Host component Host Molecular definition
Neurons H Serum IgG
Sciatic nerve homogenate H Serum IgG
Heart homogenate H T cells
Cardiomyocytes H, Rb T cells
Heart homogenate M T cells
Cardiac myosin M CD4+ T cells, serum IgG
43 kDa muscle glycoprotein M Serum IgG
Nervous tissue, Heart and M Serum IgG
skeletal muscle
2nd extracellular loop, M2 H, M Serum IgG
cholinergic receptor
2nd extracellular loop, β1 M Serum IgG
adrenergic receptor
Small nuclear ribonucleoprotein H Serum IgG
M, mouse; H, human; Rb, rabbit. Adapted from CUNHA-NETO et al., 2004.
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peptides elicits cardiac myosin-crossreactive T cell clones (ABEL et
al., 1997; IWAI et al. 2005). The presence of molecular mimicry
between cardiac myosin and T. cruzi protein B13 suggests, at least in
part, that a cellular effector response against cardiac myosin triggered
by autoimmune recognition might be involved in the development of
CCC heart lesions.
Autoimmune and T. cruzi-specific responses secondary to parasite
persistence are not incompatible or mutually exclusive in Chagas
disease, and it is likely that a combination of both should be involved
in the establishment of heart tissue lesions. A consensus among the
scientific community is that inflammation - triggered either by the
parasite or by autoantigens - certainly has a role in CCC pathogenesis.
In this scenario, inflammatory cytokines seem to be the key players,
as discussed below.
Inflammation and the role of cytokines: Data from murine models
show that inflammatory cytokines play a central role in T. cruzi
infection. The innate and adaptive immune responses triggered by the
parasite and its derived surface molecules, such as GPI anchors, during
the acute phase lead to exacerbated production of inflammatory
cytokines, including IL-12, TNF-α, and IFN-γ, and chemokines such
as CCL3 (MIP-1α), CXCL10 (IP-10), and CCL5 (RANTES) (CUNHA-
NETO et al., 1998; TEIXEIRA et al., 2002). Macrophages and dendritic
cells endocytose parasites and, with the ensuing expression of IL-12
and costimulatory molecules, prime IFN-γ-producing specific T cells
that migrate to the target organs in response to chemokines produced
in infected tissues (reviewed in TEIXEIRA et al., 2002). These steps,
which occur shortly after infection, help to build up cellular and humoral
immune responses to T. cruzi, leading to control - but not complete
elimination - of parasitism.
The initial innate immune response against T. cruzi is believed to
be mediated in part by Toll like receptors (TLR), pattern recognition
receptors that play an essential role in the recognition of microbial
components by the innate immune system (CAMPOS & GAZZINELLI,
2004). Infection of mice deficient of TLR2 and its adaptor molecule
MyD88 resulted in impaired production of inflammatory cytokines,
along with enhanced parasitemia and mortality (CAMPOS et al., 2004).
Moreover, OLIVEIRA and co-workers showed that TLR4 is important
in the recruitment of neutrophils after injection of T. cruzi surface
glycoinositolphospholipids, and infection of C3H/HeJ mice, a strain
naturally deficient in TLR4, resulted in higher parasitemia and earlier
mortality as compared to TLR4 sufficient mice (OLIVEIRA et al.,
2004). Recent data show that mice deficient in TLR9 and both TLR9
and TLR2 display decreased in vivo IL-12/IFN-γ responses upon T.
cruzi infection and thus enhanced susceptibility to infection (BAFICA
et al., 2006), suggesting that TLR2 and TLR9 cooperate in the control
of parasite replication. These results indicate that T. cruzi is recognized
by TLRs, and that the activation of cytokine production by these innate
receptors plays an important role in host defense.
The use of cytokine deficient mouse models has provided important
findings that helped understand the mechanisms of immunity to T.
Table 2
Molecular mimicry after T. cruzi infection
Host component T. cruzi antigen Host Molecular definition
Neurons, liver, kidney, testis ? M, R Mab
Neurons Sulphated glycolipids H, R Mab, sera
47 kDa neuron protein FL-160 H rDNA, AS
Heart and skeletal muscle Microsomal fraction H, M Mab, serum IgG
Smooth and striated muscle 150 kDa protein H, M Serum IgG
Human cardiac myosin heavy chain B13 protein H rDNA, Ab T cell clones
Human cardiac myosin heavy chain Cruzipain  M Ab
95KDa myosin tail T. cruzi cytoskeleton M Mab
Skeletal muscle Ca++ dependent SRA SRA H, Rb AS, serum IgG
Glycosphingolipids Glycosphingolipids  H, M Serum IgG
MAP (brain) MAP  H, M rDNA, AS
Myelin basic protein T. cruzi soluble extract  M Serum IgG, T cells
28 kDa lymphocyte membrane protein 55 kDa membrane protein  H, M Mab
23 kDa ribosomal protein 23 kDa ribosomal protein H Ab
Ribosomal P protein Ribosomal P protein H rDNA, Ab, SP
38-kDa heart antigen R13 peptide from ribosomal protein P1, P2  M IgG1, IgG2
β1-adrenoreceptor M2 muscarinic receptor Ribosomal P0 and P2β proteins H rDNA, Ab, SP
β1-adrenoreceptor M2 cholinergic receptor 150 kDa protein H, M Mab
Cardiac muscarinic Acetylcholine receptors(mAChR) ? H Ab
Cardiac muscarinic Acetylcholine receptors(mAChR) Cruzipain M Immunization with
cruzipain
Cha antigen SAPA, 36KDa TENU2845 M Ab, T cells
M, mouse; H, human; Rb, rabbit; R, rat; AS, antiserum; Ab, patient antibody; Mab, monoclonal antibody; rDNA, recombinant DNA; SP, synthetic peptides. Adapted
from CUNHA-NETO et al., 2004.
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cruzi. Production of inflammatory cytokines is associated with
protection against T. cruzi infection, and TNFR1 or IFNγ deficient
mice succumb to infection more rapidly than wild type mice
(ALIBERTI et al., 2001; MICHAILOWSKY et al., 2001). On the other
hand, complete absence of anti-inflammatory cytokines has severe
negative effects on the infected host. IL-10 deficient mice infected
with T. cruzi, despite efficient parasite control, develop a syndrome
similar to endotoxic shock due to the enhanced production of TNF-α
and IFN-γ (HOLSCHER et al., 2000). Furthermore, it has been reported
that susceptible mouse strains display higher production of TNF-α
than resistant strains upon T. cruzi infection (RUSSO et al., 1989).
Moreover, elevated levels of TNF-α were associated with higher
parasitemia, wasting, and mortality during acute T. cruzi infection
(TRUYENS et al., 1999), suggesting a negative role for elevated TNF-
α production during the acute phase. Collectively, these results point
to the importance of both inflammatory and anti-inflammatory
responses during T. cruzi infection.
More recently, using a single combination of parasite strain (Y
strain) and a genetically heterogeneous host (Syrian hamster) our group
observed two distinct disease profiles upon acute T. cruzi infection:
(1) absence of systemic acute phase signs such as lethargy and weight
loss, low cardiac parasitism, and low mRNA expression of TNF-α,
IFN-γ, IL-10 and CCL3 (MIP-1α); and (2) presence of acute phase
signs, high cardiac parasitism and markedly increased expression of
cytokines (BILATE et al., 2008 in press). The presence of acute phase
signs and high cardiac parasitism in a subset of infected hamsters could
be the underlying reason for the increased expression of cytokines and
chemokines. The dichotomy with respect to clinical signs and intensity
of cardiac parasitism in T. cruzi-infected hamsters suggests that a subset
of animals is able to control parasitism - either systemically or locally
- in a more effective manner. Since Syrian hamsters are outbred, it is
possible that this difference may be based on a genetic component.
Recent reports have addressed the role of TGF-β, a cytokine produced
by several cell types, including T cells and fibroblasts, in T. cruzi cell
invasion cell cycle. WAGHABI and co-workers showed that SB-431542,
an inhibitor of the TGF-β type I receptor, impairs cardiomyocyte invasion
by T. cruzi and trypomastigote differentiation and release, and reduces
the number of parasites per infected cell (WAGHABI et al., 2007).
Previous work from the same group suggested that T. cruzi uses host-
cell TGF-beta to maintain its own intracellular life-cycle (WAGHABI
et al., 2005). These findings suggest that TGF-β could be a potential
target for the treatment of Chagas disease.
The inflammatory infiltrate found in heart tissue of CCC patients
contains macrophages, granzyme-expressing CD8+ T cells, and CD4+
T cells (HIGUCHI et al, 1993). Data from CCC patients show that
cytokine profile is shifted towards Th1 cytokines such as IFN-γ with
suppression of Th2-type cytokines such as IL-4 (RIBEIRÃO et al.,
2000; ABEL et al., 2001), and elevated plasma levels of TNF-α
(FERREIRA, 2003). Furthermore, peripheral blood mononuclear cells
from chronic CCC patients produce more IFN-γ and less IL-10 (ABEL
et al., 2001; GOMES et al., 2003) than indeterminate Chagas disease
patients, reinforcing the hypothesis that CCC patients develop an
exacerbated Th1 immune response. Moreover, increased myocardial
expression of adhesion molecules, HLA class I and II, chemokines
MCP-1, IP-10 and MIG and their receptors CCR2 and CXCR3, and
cytokines IFN-γ, TNF-α, IL-15, IL-6 and IL-4 has also been reported
(reviewed in CUNHA-NETO et al., 2006; FONSECA et al., 2007).
Gene expression profiling of CCC myocardial tissue showed that 15%
of genes known to be selectively up-regulated in CCC are IFN-γ-
inducible (CUNHA-NETO et al., 2005). Exposure of neonatal murine
cardiomyocytes to IFN-γ and MCP-1 upregulates expression of atrial
natriuretic factor (CUNHA-NETO et al., 2005), a marker of
cardiomyocyte hypertrophy and heart failure, suggesting that IFN-γ
may directly modulate gene expression in myocardial cells. Together,
these observations suggest that IFN-γ-mediated chronic myocardial
inflammation could contribute to the pathogenesis of CCC.
Finally, work from our group and others has brought to attention
the complex role of inflammatory cytokines in CCC pathogenesis.
Given that TNF-α levels are increased among CCC patients as compared
to IND individuals (FERREIRA et al., 2003; TALVANI et al., 2004),
and that T cells infiltrating the heart of CCC patients predominantly
produce IFN-γ and TNF-α (ABEL et al., 2001), one may hypothesize
that inflammatory cytokine inhibition could ameliorate CCC
progression. In order to test this, we used the hamster model for CCC
(RAMIREZ et al., 1994; BILATE et al., 2003) to evaluate whether
TNF-α blockade could attenuate disease progression. To our surprise,
blocking TNF-α with a soluble TNF-α receptor (Etanercept) during
the chronic phase of T. cruzi infection worsened CCC, as shown by
impaired cardiac function, a hallmark of human CCC (BILATE et al.,
2007). Severity of cardiomyopathy was not due to increased tissue or
blood parasitism, direct drug toxicity on intact myocardium, increased
myocardial fibrosis, or increased myocarditis and inflammatory
cytokine expression in the heart. However, Etanercept treatment induced
increased expression of IL-10 and decreased expression of iNOS mRNA
in the myocardium, which could be associated with the observed
outcome either direct or indirectly. The worsening of ventricular
function in Etanercept-treated animals suggests that the absence of
TNF activity during the chronic phase of T. cruzi infection in hamsters
was detrimental to cardiac function.
To summarize, the data discussed above support the notion that
inflammatory cytokines and chemokines are essential for immune-
mediated control of parasite dissemination. On the other hand,
regulatory or anti-inflammatory cytokines are absolutely necessary to
counteract the otherwise destructive effect of exacerbated inflammation,
which often results in tissue damage and may lead to death of the host.
Collectively, the results obtained so far highlight the importance of
maintaining the balance between a strong effector immune response
that leads to tissue damage and a regulated immune response that will
help maintain tissue homeostasis.
Genetic studies: Differential clinical progression of the disease
occurs in the presence of persistent, low-grade infection, and the
development of CCC in only one-third of infected individuals points
to an element of genetic susceptibility. This is reinforced by the finding
of familial aggregation of cases of CCC (ZICKER et al., 1990). It is
thus likely that gene polymorphisms affecting the immune response
could also influence differential progression towards CCC among T.
cruzi-infected patients. However, HLA-disease association studies
yielded conflicting results (FERNANDEZ-MESTRE et al., 1998;
DEGHAIDE et al., 1998; COLORADO et al., 2000; FAÉ et al., 2000),
and have failed to disclose relevant genes leading to the clinical
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dichotomy observed. This may have been due to the genetic
heterogeneity of the populations in the different regions and countries
under study. Polymorphisms in immune-response genes have also been
assessed for association with CCC. The 59029A allele of chemokine
receptor CCR5, reported to induce increased expression of the receptor,
was shown to be more frequent among asymptomatic patients in a
Peruvian study (CALZADA et al., 2001), suggesting a protective effect.
RODRIGUEZ-PEREZ et al. have reported an association between
tumor necrosis factor-α promoter polymorphisms (TNF -308A
promoter allele) and susceptibility to cardiomyopathy in a Mexican
population (RODRÍGUEZ-PÉREZ et al., 2005). A longitudinal study
conducted by our group showed that Brazilian patients carrying the
TNF2 or TNFa2 alleles display a significantly shorter survival compared
to those carrying other alleles (DRIGO et al., 2006). However, recent
data show no significant differences either between CCC and IND
patients, or among CCC patients according to severity of
cardiomyopathy with respect to TNFa or -308 TNF promoter
polymorphisms (DRIGO et al., 2007). A similar lack of association
was observed in a Peruvian study of the -238 TNF promoter
polymorphic site (BERAÚN et al., 1998). Together, these results
indicate that, at least in South America, TNF polymorphisms are
associated neither with CCC development nor with progression to more
severe forms of cardiomyopathy in Brazilian Chagas disease patients,
although the same polymorphisms may be important for mortality
among end-stage CCC patients. More recently, further studies have
disclosed an association between CCC and polymorphisms in several
immune response genes. Innate immunity genes are attractive
candidates for studying differential susceptibility in the development
of CCC since parasitism during the acute phase is controlled by the
innate immune response. Variants of BAT1, a putative anti-
inflammatory gene associated with down-regulation of TNF-α and IL-
6, are predictive of the development of CCC (RAMASAWMY et al.,
2006). The chemokine MCP-1 (CCL2) variant behaves as a genetic
modifier of clinical outcome in T. cruzi infection, subjects with the
CCL2 -2518AA genotype showing 4-fold greater risk of developing
CCC than those without this genotype (RAMASAWMY et al., 2006).
Another associated gene is IKBL, which is homologous to IκBα, an
inhibitor of NFκB that plays a key role in innate immunity. The
likelihood of developing CCC is three- and two-fold higher among T.
cruzi-infected individuals bearing the IKBL - 62 genotypes AA and
AT, respectively, than among homozygous TT individuals infected with
T. cruzi. Similarly, patients with genotype - 262AA show three-fold
higher risk of developing CCC (RAMASAWMY et al., 2008). The
presence of such variants among CCC patients may lead to less efficient
downregulation of inflammatory responses, thus contributing to the
elevated production of inflammatory cytokines in patients with CCC.
Proteomics: Novel technological approaches, such as high-
throughput proteomics, now allow for direct evaluation of large-scale
protein profiles and identification of differentially expressed proteins
(ARRELL et al., 2001), contributing to our understanding of disease
mechanisms and aiding the discovery of potential therapeutic targets.
Our group has recently described an inventory of myocardial
proteins from patients with severe CCC. This has allowed us to identify
proteins with high and low abundance in the tissue, including proteins
with structural, metabolic, stress, apoptosis and immune response
functions (TEIXEIRA et al., 2006). It would be interesting to investigate
whether the expression of cardiac proteins differs between severe CCC
patients and mild CCC or IND subjects. However, since this comparison
cannot be performed due the impossibility of obtaining samples from
the two latter groups, one must rely on animal models in order to clarify
this issue. By combining the outbred hamster model for Chagas disease
with proteomic analysis, our group has also shown that susceptibility
to acute T. cruzi infection is associated not only with high parasite
load and cytokine expression in the heart, but also with differential
myocardial expression of structural/contractile, stress response, and
metabolism proteins (BILATE et al., 2008 in press). These results
suggest a link between parasitism, inflammation and cardiomyocyte
response. Although the functional data needed to ascertain the role of
myocardial protein expression in the pathogenesis of the disease are
still lacking, it is very likely that T. cruzi infection per se and/or parasite-
triggered inflammation can play a role in cardiac damage.
Concluding remarks: Chagas disease cardiomyopathy is an
inflammatory disease caused by protozoan T. cruzi that affects only
30% of the infected individuals. Data from both murine models and
human studies support the view that autoimmune, as well as parasite-
driven immune responses may both play a role in generating heart
lesions, along with inflammatory cytokines and chemokines. Moreover,
the ability of the host to cope with the infection may determine the
balance between the inflammatory vs. anti-inflammatory immune
responses.
Although much is known about the immunopathogenesis of Chagas
disease, certain questions remain open. These include the factors
involved in the dichotomy of clinical outcomes among cardiomyopathy
patients and indeterminate individuals, and the mechanisms by which
parasites manage to survive - essentially unnoticed - for such extended
periods within the host. Knowing how the parasite is able to invade
cells and circumvent the host’s immune response will certainly aid in
the development of effective drugs and immunotherapy for the millions
of patients still afflicted by this neglected disease.
RESUMO
Cardiomiopatia chagásica: conceitos atuais de doença antiga
A doença de Chagas continua sendo importante problema de saúde
pública uma vez que cerca de 10 milhões de indivíduos ainda estão
infectados pelo T. cruzi. Décadas após a infecção primária,
aproximadamente 30% dos indivíduos podem desenvolver uma
cardiomiopatia inflamatória crônica, a chamada Cardiomiopatia
Chagásica Crônica (CCC). Dados de modelos murinos e de estudos
em humanos apóiam a visão de que tanto respostas auto-imunes como
as determinadas pelo parasita em conjunto com citocinas e quimiocinas
inflamatórias participam da geração das lesões cardíacas típicas da
CCC. A presente revisão tem como objetivo sumarizar os recentes
avanços no entendimento da imunopatogênese da Cardiomiopatia
Chagásica Crônica.
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